Luis de Sisternes1, Julia Hu2, Daniel L Rubin3, Michael F Marmor2. 1. Department of Radiology Stanford University, Stanford, California, United States. 2. Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, United States. 3. Department of Radiology Stanford University, Stanford, California, United States 3Department of Medicine (Biomedical Informatics), Stanford University, Stanford, California, United States.
Abstract
PURPOSE: To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT). METHODS: A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically. RESULTS: The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization. CONCLUSIONS: Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.
PURPOSE: To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT). METHODS: A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically. RESULTS: The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQtoxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization. CONCLUSIONS:Hydroxychloroquineretinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.
Authors: Jean-Claude Mwanza; Mary K Durbin; Donald L Budenz; Fouad E Sayyad; Robert T Chang; Arvind Neelakantan; David G Godfrey; Randy Carter; Alan S Crandall Journal: Ophthalmology Date: 2012-02-23 Impact factor: 12.079
Authors: Michael F Marmor; Ulrich Kellner; Timothy Y Y Lai; Jonathan S Lyons; William F Mieler Journal: Ophthalmology Date: 2011-02 Impact factor: 12.079
Authors: Luis de Sisternes; Gowtham Jonna; Jason Moss; Michael F Marmor; Theodore Leng; Daniel L Rubin Journal: Biomed Opt Express Date: 2017-02-28 Impact factor: 3.732
Authors: Mehmet Bulut; Melih Akıdan; Onursal Gözkaya; Muhammet Kazım Erol; Ayşe Cengiz; Hasan Fatih Çay Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-08-29 Impact factor: 3.117
Authors: Ali M Allahdina; Paul F Stetson; Susan Vitale; Wai T Wong; Emily Y Chew; Fredrick L Ferris; Paul A Sieving; Catherine Cukras Journal: Invest Ophthalmol Vis Sci Date: 2018-04-01 Impact factor: 4.799